In conclusion, p53 is an important tumour suppressor gene that deserves additional investigation as a marker of therapeutic activity in CRC, and results obtained in the present study suggest that analysis of the exact status of p53 (e.g. wt or mt and functionally active or not) could be useful to predict clinical outcome after chemotherapy with TS inhibitors. The gene discussed is TYMS; the disease is colorectal carcinoma.